All times are interesting times, but the summer of 2016 was especially interesting. That July, as a Twitter user named Katie ...
ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
Autonomous AI agents with wallet access can trigger irreversible and costly on-chain transactions without human oversight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results